Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes

AIMS: Doxorubicin (DOX) is among the most effective chemotherapies used in paediatric cancer patients. However, the clinical utility of DOX is offset by its well-known cardiotoxicity, which often does not appear until later in life. Since hypertension significantly increases the risk of late-onset h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Res
Main Authors: Matsumura, Nobutoshi, Zordoky, Beshay N, Robertson, Ian M, Hamza, Shereen M, Parajuli, Nirmal, Soltys, Carrie-Lynn M, Beker, Donna L, Grant, Marianne K, Razzoli, Maria, Bartolomucci, Alessandro, Dyck, Jason R B
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6054166/
https://ncbi.nlm.nih.gov/pubmed/29566148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvy064
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados